- Witschel, M; Röhl, F; Niggeweg, R; Newton, T In search of new herbicidal inhibitors of the non-mevalonate pathway. Pest Manag Sci 69: 559-63 (2013)
- Vlattas, I; Dellureficio, J; Ku, E; Bohacek, R; Xiaolu, Zhang Inhibition of mevalonate 5-pyrophosphate decarboxylase by a proline-containing transition state analog Bioorg Med Chem Lett 6: 2091-2096 (1996)
- PubChem, PC Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK Dose Response PubChem Bioassay (2007)
- PubChem, PC Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC - Secondary Assay PubChem Bioassay (2008)
- PubChem, PC Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC Dose Response PubChem Bioassay (2007)
- ChEMBL_105297 (CHEMBL714139) Compound was evaluated for its inhibitory activity against Mevalonate 5-pyrophosphate decarboxylase
- ChEMBL_105298 (CHEMBL714140) Compound was evaluated for its inhibitory activity against Mevalonate 5-pyrophosphate decarboxylase
- ChEBML_201933 In vitro inhibition of pig liver microsomal squalene epoxidase (SE) by measuring the extend of cholesterol radiolabeling after incubation with [14C]mevalonate
- Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK Dose Response Southern Research Molecular Libraries Screening Center (SRMLSC) Southern Research Institute (Birmingham, Alabama) NIH Molecular Libraries Screening Centers Network (MLSCN) Assay Provider: Dr. Thomas S. Leyh, Albert Einstein College of medicine of Yeshiva University Streptococcus pneumonia (SP) takes the lives of nearly 4,000 people daily and antibiotic resistant strains are becoming an increasing problem. Because of this, the discovery of drugs targeting novel pathways such as the mevalonate pathway has become increasingly important. The pathway produces isopentyl diphosphate (the molecular building block of isoprenoids) and is essential for the survival of the pathogen in mouse lung and serum. The mevalonate pathway is comprised of three consecutive reactions that are catalyzed by the enzymes mevalonate kinase (MK; E.C. 2.7.1.36), phosphomevalonate kinase (PMK; E.C. 2.7.4.2), and diphosphomevalonate decarboxylase (PDM-DC; E.C. 4.1.1.33). MK catalyzes the ATP dependent conversion o
- High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases - Confirmatory Screen Southern Research Molecular Libraries Screening Center (SRMLSC) Southern Research Institute (Birmingham, Alabama) NIH Molecular Libraries Screening Centers Network (MLSCN) Submitted by Dr. Cynthia Stauffacher (Purdue University) Award: 1-R03-MH082373-01 A number of common human pathogens, including Enterococcus faecalis, Streptococcus pneumoniae, and Staphylococcus aureus, are becoming progressively more resistant to antibiotics and pose a serious public health threat, especially to post-surgical and trauma patients. Therefore, the discovery of drugs targeting novel pathways in these pathogens has become increasingly important. The synthesis of isoprenoids, which in these gram-positive pathogenic bacteria (Hedl, 2002) occurs exclusively via the mevalonate pathway, is essential for their survival. The central mevalonate pathway enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR; EC 1.1.1.34), reduces HMG-CoA to mevalonate using NADPH (Hedl, 2004). Bacterial HMG-CoA redu
- Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC - Secondary Assay Southern Research Molecular Libraries Screening Center (SRMLSC) Southern Research Institute (Birmingham, Alabama) NIH Molecular Libraries Screening Centers Network (MLSCN) Assay Provider: Dr. Thomas S. Leyh, Albert Einstein College of Medicine of Yeshiva University Award: R03 MH078936-01 Streptococcus pneumoniae takes the lives of nearly 4,000 people daily and antibiotic resistant strains are becoming an increasing problem. Because of this, the discovery of drugs targeting novel pathways has become increasingly important. The mevalonate pathway produces isopentenyl diphosphate (the molecular building block of isoprenoids) and is essential for the survival of the pathogen in mouse lung and serum. The biosynthesis of isopentenyl diphosphate involves three consecutive reactions that are catalyzed by the enzymes mevalonate kinase (MK; E.C. 2.7.1.36), phosphomevalonate kinase (PMK; E.C. 2.7.4.2), and diphosphomevalonate decarboxylase (DPM-DC; E.C. 4.1.1.33). DPM-DC catalyzes the ATP-
- Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC Dose Response Southern Research Molecular Libraries Screening Center (SRMLSC) Southern Research Institute (Birmingham, Alabama) NIH Molecular Libraries Screening Centers Network (MLSCN) Assay Provider: Dr. Thomas S. Leyh, Albert Einstein College of Medicine of Yeshiva University Streptococcus pneumoniae takes the lives of nearly 4,000 people daily and antibiotic resistant strains are becoming an increasing problem. Because of this, the discovery of drugs targeting novel pathways has become increasingly important. The mevalonate pathway produces isopentenyl diphosphate (the molecular building block of isoprenoids) and is essential for the survival of the pathogen in mouse lung and serum. The biosynthesis of isopentenyl diphosphate involves three consecutive reactions that are catalyzed by the enzymes mevalonate kinase (MK; E.C. 2.7.1.36), phosphomevalonate kinase (PMK; E.C. 2.7.4.2), and diphosphomevalonate decarboxylase (DPM-DC; E.C. 4.1.1.33). DPM-DC catalyzes the ATP-dependent conversion of (R